NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Thursday morning,Benzinga reports. They currently have a $19.00 price target on the stock.

Several other equities analysts have also commented on NRXP. D. Boral Capital reiterated a “buy” rating and issued a $31.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, March 17th. Ascendiant Capital Markets upped their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd.

NRx Pharmaceuticals Stock Up 0.5 %

NASDAQ NRXP opened at $2.08 on Thursday. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $6.01. The stock has a market cap of $35.19 million, a price-to-earnings ratio of -0.97 and a beta of 1.22. The business has a fifty day moving average of $2.82 and a 200-day moving average of $2.03.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter valued at about $56,000. Millennium Management LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter valued at about $61,000. Anson Funds Management LP grew its position in NRx Pharmaceuticals by 30.3% during the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after acquiring an additional 43,135 shares during the period. AdvisorShares Investments LLC boosted its position in shares of NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after buying an additional 180,229 shares during the period. Finally, Sassicaia Capital Advisers LLC purchased a new stake in shares of NRx Pharmaceuticals in the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.